Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (72607)	3/18/2001 4:51:51 PM
From: Sea Otter	Read Replies (2) \| Respond to of 99985

I think the mab (monoclonal antibody) firms hold the most promise, relative to valuations. The science here has matured and products are coming through the pipeline. Not visible in the general public/investor's radar yet, but I suspect will make a huge splash over the next few years. Very sexy stuff - and with profitable business models as well. Examples are TTP (mental illness mab), IMCL (angiogenesis and cancer mab), IMGN (cancer mab platform). All have gotten whacked by the bear. TTP and IMCL are in Phase 3. IMGN is more speculative, in Phase 1. Do you invest in this space? Recommendations?